While the world is making grounds ready for the battle against the new enemy Omicron COVID variant, the UK’s Medicines and Healthcare products Regulatory Agency as a ray of hope approved a Covid-19 treatment.
Developed by GSK and Vir Biotechnology, the drug named ‘Sotrovimab’ was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease.
Sotrovimab is an investigational monoclonal antibody that retains activity against key mutations of the new Omicron variant, including those found in the binding site of Sotrovimab. The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high amount of mutations on that protein.
Last month, the UK became the first country to approve molnupiravir, a potentially game-changing COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics.